EGA
ECYT

Eagle Global Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Eagle Global Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-99,200
Closed -$307K – 422
2016
Q3 		$307K Sell
99,200
-53,960
-35% -$168K 0.01% 265
2016
Q2 		$492K Hold
153,160
– – 0.01% 195
2016
Q1 		$475K Buy
153,160
+25,070
+20% +$81.9K 0.02% 206
2015
Q4 		$514K Buy
128,090
+13,850
+12% +$63.8K 0.02% 208
2015
Q3 		$523K Buy
114,240
+38,400
+51% +$201K 0.02% 197
2015
Q2 		$394K Buy
75,840
+50,480
+199% +$303K 0.01% 249
2015
Q1 		$159K Buy
+25,360
New +$146K ﹤0.01% 327

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eagle Global Advisors's ECYT Position: Q4 2016 in Review

Eagle Global Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2016, closing a stake of 99,200 shares — an estimated $307K sold.

Eagle Global Advisors first reported a position in ECYT in Q1 2015 and held it in 7 quarters. The position peaked at $523K in Q3 2015. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

  • Eagle Global Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 99,200 Endocyte, Inc. Common Stock shares in Q4 2016, an estimated $307K.
  • Eagle Global Advisors first reported a position in Endocyte, Inc. Common Stock in Q1 2015 and held it in 7 quarters.
  • Eagle Global Advisors's Endocyte, Inc. Common Stock position peaked at $523K in Q3 2015.
  • 96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on Eagle Global Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.